Circulating interleukin-6 concentration and cognitive decline in old age: The PROSPER study

Journal of Internal Medicine

Volumn 274, Issue 1, 2013, Pages 77-85

  Mooijaart, S P ^a,b   Sattar, N ^c   Trompet, S ^a   Lucke, J ^a   Stott, D J ^d   Ford, I ^d   Jukema, J W ^a   Westendorp, R G J ^a,b   de Craen, A J M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Consortium for Healthy Ageing   (Netherlands)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Aging; Cognition; Inflammation; Interleukin 6

Indexed keywords

INTERLEUKIN 6;

AGED; ALLELE; APTITUDE TEST; ARTICLE; ATTENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; PRIORITY JOURNAL; PROMOTER REGION; SENESCENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COGNITION; COGNITION DISORDERS; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROSS-SECTIONAL STUDIES; EXECUTIVE FUNCTION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INFLAMMATION; INTERLEUKIN-6; IRELAND; MALE; NETHERLANDS; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRAVASTATIN; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT; RISK FACTORS; SCOTLAND; STROKE;

EID: 84879096484     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12052     Document Type: Article

References (23)

1. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999; 53: 1937-42.
2. Yaffe K, Lindquist K, Penninx BW et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003; 61: 76-80.
3. Engelhart MJ, Geerlings MI, Meijer J et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004; 61: 668-72.
4. Wright CB, Sacco RL, Rundek TR, Delman JB, Rabbani LE, Elkind MS. Interleukin-6 is associated with cognitive function: the Northern Manhattan Study. J Stroke Cerebrovasc Dis 2006; 15: 34-8.
5. Schram MT, Euser SM, de Craen AJ et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 2007; 55: 708-16.
6. Gimeno D, Marmot MG, Singh-Manoux A. Inflammatory markers and cognitive function in middle-aged adults: the Whitehall II study. Psychoneuroendocrinology 2008; 33: 1322-34.
7. Papassotiropoulos A, Hock C, Nitsch RM. Genetics of interleukin 6: implications for Alzheimer's disease. Neurobiol Aging 2001; 22: 863-71.
8. Huth C, Heid IM, Vollmert C et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 2006; 55: 2915-21.
9. Huth C, Illig T, Herder C et al. Joint analysis of individual participants' data from 17 studies on the association of the IL6 variant -174G>C with circulating glucose levels, interleukin-6 levels, and body mass index. Ann Med 2009; 41: 128-38.
10. Dai L, Liu D, Guo H, Wang Y, Bai Y. Association between polymorphism in the promoter region of Interleukin 6 (-174 G/C) and risk of Alzheimer's disease: a meta-analysis. J Neurol 2012; 259: 414-9.
11. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
12. Shepherd J, Blauw GJ, Murphy MB et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999; 84: 1192-7.
13. Trompet S, van Vliet P, de Craen AJ et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010; 257: 85-90.
14. Houx PJ, Shepherd J, Blauw GJ et al. Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry 2002; 73: 385-9.
15. Sattar N, Murray HM, Welsh P et al. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med 2009; 6: e1000099.
16. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-76.
17. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H, Hori M. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke 2005; 36: 768-72.
18. van Exel E, Gussekloo J, Houx P et al. Atherosclerosis and cognitive impairment are linked in the elderly. The Leiden 85-plus Study. Atherosclerosis 2002; 165: 353-9.
19. Campbell IL, Stalder AK, Chiang CS et al. Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol Psychiatry 1997; 2: 125-9.
20. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002; 50: 2041-56.
21. Naitza S, Porcu E, Steri M et al. A genome-wide association scan on the levels of markers of inflammation in Sardinians reveals associations that underpin its complex regulation. PLoS Genet 2012; 8: e1002480.
22. Mooijaart SP, Sattar N, Trompet S et al. C-reactive protein and genetic variants and cognitive decline in old age: the PROSPER study. PLoS ONE 2011; 6: e23890.
23. The Interleukin-6 Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 2012; 379: e23890.